BMY
Bristol-Myers Squibb Company · NYSE
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website bms.com
- Employees(FY) 34300
- ISIN US1101221083
Performance
-1.59%
1W
-15.62%
1M
-8.64%
3M
-11.96%
6M
-12.27%
YTD
-31.15%
1Y
Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Onureg for the treatment of adult patients with AML; Inrebic, an oral kinase inhibitor indicated for the treatment of myelofibrosis; Camzyos for the treatment of adults with symptomatic obstructive HCM to enhance functional capacity and symptoms; Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane, a protein-bound chemotherapy product. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Investment Analysis Report: Bristol-Myers Squibb Company (BMY)
Overview:
Bristol-Myers Squibb Company (BMY) operates in the Health Technology sector, specifically in the Pharmaceuticals: Major industry. The company has a market capitalization of $104.47 billion. In this report, we will conduct a comprehensive analysis of BMY's financial health, ...
Technical Analysis of BMY 2024-05-03
Overview:
In analyzing the technical indicators for BMY over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key aspects, we aim to offer valuable insights and predictions for potential investo...
Recent News & Updates
- 2024-05-04 07:01
- 2024-05-03 22:34
- 2024-05-01 08:00
- 2024-05-01 01:52
Alphabet Inc. (NASDAQ:GOOG) Q1 2024 Earnings Call Transcript(Insidermonkey)
- 2024-04-30 20:00
- 2024-04-29 20:37
- 2024-04-29 17:00
- 2024-04-29 06:00
- 2024-04-28 18:00
- 2024-04-27 09:48
- 2024-04-26 06:59
- 2024-04-26 04:41
- 2024-04-26 03:35
- 2024-04-25 23:55
- 2024-04-25 23:50
- 2024-04-25 23:48
- 2024-04-25 21:49
- 2024-04-25 18:59
- 2024-04-25 14:02
Analyst Report: Bristol-Myers Squibb Company(Morningstar Research)
- 2024-04-25 11:42
Heard on the Street: Bristol-Myers Goes From Big Pharma to Little Pharma(The Wall Street Journal)
- 2024-04-25 06:59
- 2024-04-25 01:32
- 2024-04-24 18:59
- 2024-04-23 01:56
- 2024-04-22 18:59
- 2024-04-22 06:59
- 2024-04-21 18:59
- 2024-04-21 08:00
Is Bristol-Myers Squibb (NYSE:BMY) Using Too Much Debt?(Simply Wall St.)
- 2024-04-15 10:00
- 2024-04-11 09:10
Page 1 of 10
previousnext